Considering the effectiveness of SGLT2 inhibitors in managing CKD in diabetic and non-diabetic individuals and the increased SGLT2 expression in obesity [92], studying the potential of SGLT2 inhibitors in managing obesity-related renal damage and obesity-associated PT modifications is a promising research area. The gene discussed is SLC5A2; the disease is obesity disorder.